福耀玻璃(03606.HK):擬增發不超1.01億股H股申請獲中國證監會核准
格隆匯 4 月 29日丨福耀玻璃(03606.HK)發佈公吿,2021年4月29日,公司收到中國證監會核發的《關於核准福耀玻璃工業集團股份有限公司增發境外上市外資股的批覆》(證監許可[2021]1495號)。根據證監批覆,中國證監會核准公司有關本次發行的申請,具體如下:
一.核准公司增發不超過101,126,240股H股,每股面值人民幣1元,全部為普通股。
二.本次發行完成後15個工作日內,公司應將本次發行的情況書面報吿中國證監會。
三.本批覆自核準發行之日起12個月內有效。
四.公司在本次發行過程中,應嚴格遵守境內外有關法律、法規和規則。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.